New Competitor in MMJ Market sets High Standards

PI Financial is initiating coverage of Emblem (TSXV:EMC) with a BUY rating (Risk rating: SPECULATIVE) with a 12-month target of $3.25.
As quoted in the report:

Emblem Corp. is a fully integrated Canadian medical marijuana, healthcare and cannabinoid-based pharmaceutical company licensed to carry on business as a producer and seller of medical cannabis.
Strong management. Gordon Fox leads a strong team of professionals with deep roots in the medical field. Harvey Shapiro, President of GrowWise a joint venture partner, co-founded an independent pharmacy chain with Gordon Fox as well as co-founding Dynacare – a medical diagnostic services company.John Stewart, President of Emblem’s pharmaceutical division was CEO of Purdue Pharma Canada.
Emblem has a state-of-the-art facility in Ontario, which boasts the most up-to-date growing technology and is built on clean room standards. The facility is able to produce 700kg of MMJ and will expand shortly to 2,100kg by early 2017.

Click here to read the full report.